Loading…
Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
Background The primary aim of this study was to compare quality of life of postmenopausal breast cancer women receiving adjuvant hormone therapy with those not receiving. The secondary aims were to investigate impact of vitamin D status and type of hormone therapy (letrozole vs tamoxifen) on quality...
Saved in:
Published in: | Indian journal of surgery 2021-06, Vol.83 (Suppl 2), p.461-467 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
The primary aim of this study was to compare quality of life of postmenopausal breast cancer women receiving adjuvant hormone therapy with those not receiving. The secondary aims were to investigate impact of vitamin D status and type of hormone therapy (letrozole vs tamoxifen) on quality of life.
Settings and Design
Tertiary care hospital, prospective study (March 2016 to September 2017).
Patients and Methods
Study included postmenopausal non-metastatic breast cancer women. Patients were divided in two groups: group 1 (
n
=120) receiving adjuvant hormone therapy and group 2 (
n
=93) not receiving hormone therapy. Patients filled Functional Assessment of Cancer Therapy-Breast (FACT–B) QoL questionnaire at enrolment and 6 month later. The scores were compared between the groups.
Results
Overall basal FACT-G (
p
=0.004), FACT-B (
p
=0.003), and all other quality of life subscales scores barring social well-being were significantly better in group 2 {physical well-being (
p
=0.002), social well-being (
p
=0.037), emotional well-being (
p
=0.028), functional well-being (
p
= |
---|---|
ISSN: | 0972-2068 0973-9793 |
DOI: | 10.1007/s12262-021-02766-6 |